IO Biotech, Inc. – NASDAQ:IOBT
IO Biotech stock price today
$2.09
+1.10
+113.27%
Financial Health
0
1
2
3
4
5
6
7
8
9
Market closed
Open in about 17 hours
IO Biotech stock price monthly change
-24.03%
month
IO Biotech stock price quarterly change
-24.03%
quarter
IO Biotech stock price yearly change
-46.15%
year
IO Biotech key metrics
Market Cap | 53.83M |
Enterprise value | N/A |
P/E | -0.71 |
EV/Sales | N/A |
EV/EBITDA | 1.25 |
Price/Sales | N/A |
Price/Book | 0.38 |
PEG ratio | N/A |
EPS | -1.85 |
Revenue | N/A |
EBITDA | -90.42M |
Income | -88.49M |
Revenue Q/Q | N/A |
Revenue Y/Y | N/A |
Profit margin | 0% |
Oper. margin | 0% |
Gross margin | 0% |
EBIT margin | 0% |
EBITDA margin | N/A |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeIO Biotech stock price history
IO Biotech stock forecast
IO Biotech financial statements
| Jun 2023 | 0 | -21.17M | |
|---|---|---|---|
| Sep 2023 | 0 | -21.67M | |
| Dec 2023 | 1.11M | -26.18M | -2358.74% |
| Mar 2024 | 0 | -19.45M |
| Mar 2024 | 0 | -19.45M | |
|---|---|---|---|
| Sep 2025 | 1.11M | -18.44M | -1661.86% |
| Oct 2025 | 0 | -19.10M | |
| Dec 2025 | 0 | -19.76M |
Analysts Price target
Financials & Ratios estimates
| 2023-11-13 | -0.47 | -0.43 |
|---|---|---|
| 2024-03-05 | -0.36 | -0.4 |
| 2024-05-14 | -0.37 | -0.3 |
| Jun 2023 | 117555000 | 13.03M | 11.09% |
|---|---|---|---|
| Sep 2023 | 172553000 | 14.96M | 8.67% |
| Dec 2023 | 150718000 | 17.55M | 11.65% |
| Mar 2024 | 128158999 | 12.69M | 9.9% |
| Jun 2023 | -18.26M | -39K | -2.74M |
|---|---|---|---|
| Sep 2023 | -15.99M | -24K | 71.87M |
| Dec 2023 | -22.79M | -112K | -10K |
| Mar 2024 | -24.93M | -11K | 0 |
IO Biotech alternative data
| Sep 2023 | 57 |
|---|---|
| Oct 2023 | 57 |
| Nov 2023 | 57 |
| Dec 2023 | 57 |
| Jan 2024 | 57 |
| Feb 2024 | 57 |
| Mar 2024 | 68 |
| Apr 2024 | 68 |
| May 2024 | 68 |
| Jun 2024 | 68 |
| Jul 2024 | 70 |
IO Biotech other data
17.11%
-32.45%
of IOBT is owned by hedge funds
4.93M
-9.34M
shares is hold by hedge funds
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| Feb 2024 | 0 | 658809 |
| May 2024 | 0 | 658809 |
| Jul 2024 | 0 | 75000 |
| Dec 2024 | 66100 | 0 |
-
What's the price of IO Biotech stock today?
One share of IO Biotech stock can currently be purchased for approximately $2.09.
-
When is IO Biotech's next earnings date?
Unfortunately, IO Biotech's (IOBT) next earnings date is currently unknown.
-
Does IO Biotech pay dividends?
No, IO Biotech does not pay dividends.
-
How much money does IO Biotech make?
IO Biotech has a market capitalization of 53.83M. IO Biotech made a loss 86.08M US dollars in net income (profit) last year or -$0.3 on an earnings per share basis.
-
What is IO Biotech's stock symbol?
IO Biotech, Inc. is traded on the NASDAQ under the ticker symbol "IOBT".
-
What is IO Biotech's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of IO Biotech?
Shares of IO Biotech can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
How many employees does IO Biotech have?
As Jul 2024, IO Biotech employs 70 workers, which is 3% more then previous month and 3% more then previous quarter.
-
When IO Biotech went public?
IO Biotech, Inc. is publicly traded company for more then 3 years since IPO on 5 Nov 2021.
-
What is IO Biotech's official website?
The official website for IO Biotech is iobiotech.com.
-
How can i contact IO Biotech?
IO Biotech can be reached via phone at +45 70 70 29 80.
IO Biotech company profile:
IO Biotech, Inc.
iobiotech.comExchange:
NASDAQ
Full time employees:
74
Industry:
Biotechnology
Sector:
Healthcare
IO Biotech, Inc., a clinical-stage biopharmaceutical company, develops immune-modulating cancer therapies based on the T-win technology platform. The company's lead product candidate, IO102-IO103, which is designed to target immunosuppressive proteins, such as Indoleamine 2,3-dehydrogenase (IDO), and programmed death-ligand (PD-L1) that is in phase 2 clinical trial to treat melanoma, as well as in phase 1 clinical trial to treat lung, head and neck, bladder, and melanoma cancer. It also develops IO112, a product candidate that contains a single Arginase 1-derived peptide designed to target T cells that recognize epitopes derived from Arginase 1 for the treatment of cancers. The company was incorporated in 2014 and is based in Copenhagen, Denmark.
Ole Maaløes Vej 3
Copenhagen, 2200
Copenhagen, 2200
CIK: 0001865494
ISIN: US4497781090
CUSIP: 449778109
